Vital Signs - Healthcare News - The Analysts Perspective - June 2014

Regular Price: USD 450

Special Price USD 405

10% OFF

* Required Fields

Regular Price: USD 450

Special Price USD 405

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogen's Eloctate, Qiagen's acquisition of Primera Dx, Roche's acquisition of Genia Technologies, Cue's at-home connected lab test, and the Credihealth Teen Clinic.

Table of Contents

Vital Signs - Healthcare News - The Analyst's Perspective - June 2014Vital Signs - June 2014This week's issue




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.